Search

Displaying results 7351 - 7360 of 10000 in total
  1. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. … The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

  2. Drug

    SB-509

    go.drugbank.com/drugs/DB05579
    Investigational

    SB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.

  3. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in

  4. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

  5. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

  6. Drug

    MLN8054

    go.drugbank.com/drugs/DB13061
    Investigational

    MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

  7. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. … Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  8. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

    Categories: Adrenergic beta-1 Receptor Agonists
  9. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  10. Drug

    Cefminox

    go.drugbank.com/drugs/DB09062
    Experimental

    Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.